Sales of 989,503 hundred million yen, up 4.7% YoY; quarterly net income attributable to owners of parent of 13,646 hundred million yen, up 42.3% YoY. By segment, medical pharmaceuticals wholesale is strong, but overall operating income declines to 13,386 hundred million yen. Full-year guidance unchanged. Supplemental earnings materials to be released.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7459","jir_company_name":"Medipal Holdings Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/7459-20260805-01.pdf","jir_short_summary":"Sales of 989,503 hundred million yen, up 4.7% YoY; quarterly net income attributable to owners of parent of 13,646 hundred million yen, up 42.3% YoY. By segment, medical pharmaceuticals wholesale is strong, but overall operating income declines to 13,386 hundred million yen. Full-year guidance unchanged. Supplemental earnings materials to be released.","jir_summary":"### Overview of results\nFor the first quarter of the fiscal year ending March 2027, consolidated net sales amounted to 989,503 hundred million yen, up 4.7% YoY. However, operating income was 13,386 hundred million yen, down 4.7% YoY. Gross profit was 65,733 hundred million yen, up 1.6%. By segment, increases in medical pharmaceuticals wholesale contributed to sales growth, while margins in cosmetic and daily living goods wholesale and non-prescription drugs wholesale were pressures that persisted. Supplemental materials will be released.\n\n### Full-year outlook and financial position\nNo changes to the full-year guidance from the time of disclosure. At the end of the first quarter, total assets stood at 1,937.4 hundred million yen (11, size), net assets were 791,716 hundred million yen, and equity ratio was 33.5%. While current assets such as cash and cash equivalents increased, net income for the period may face headwinds due to amortization of goodwill. The accounting treatments related to business combinations have been finalized, and comparative information has been replaced with settled values.","jir_financial_highlights":"Sales: 989,503\u767e\u4e07\u5186 (YoY +4.7%)\nOperating income: 13,386\u767e\u4e07\u5186 (YoY \u25b34.7%)\nOrdinary income: 17,919\u767e\u4e07\u5186 (YoY \u25b31.7%)\nNet income attributable to owners of parent (quarter): 13,646\u767e\u4e07\u5186 (YoY +42.3%)\nTotal assets: 1,937,423\u767e\u4e07\u5186 (End of previous year +133,336\u767e\u4e07\u5186)","jir_category":"","jir_hashtags":"#MedipalHoldings, #FinancialSummary, #JapanStocks","jir_key_figures":"Sales: 989,503\u767e\u4e07\u5186 (YoY +4.7%)\nOperating income: 13,386\u767e\u4e07\u5186 (YoY \u25b34.7%)\nNet income attributable to owners of parent (quarter): 13,646\u767e\u4e07\u5186 (YoY +42.3%)","jir_meta_title":"\u3010Medipal Holdings Corporation\u3011Q1 20XX Earnings \u2014 Net sales 989,503 hundred million yen, Net income 13,646 hundred million yen","jir_meta_description":"Summary of Medipal Holdings' Q1 FY2027 results. Sales up 4.7% YoY, net income rising significantly; discusses segment trends and full-year outlook.","jir_og_title":"\u3010Medipal Holdings Corporation\u3011Q1 20XX Earnings","jir_og_description":"Key points of Q1 FY2027 earnings. Sales up 4.7%, net income with substantial increase. Discusses segment trends and full-year outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7774,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95578","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n